Kazia Therapeutics

Kazia Therapeutics (NASDAQ: KZIA)

Currency in -

Last close As at 22/09/2023

-1.32

▲ −0.04 (−3.03%)

Market capitalisation

22m

Overview
Price performance
Financials
Research
Thematics

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

Latest Insights

Healthcare |
Flash note

01.02.23

Kazia Therapeutics — Reinvestment period with increased R&D focus

Healthcare |
ADR Flash

19.12.22

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Healthcare |
Update

07.12.22

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Healthcare |
Flash note

01.11.22

Kazia Therapeutics — Q123 cash flows in line with our estimates

Visit Website

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

Iain Ross

Chairman
John Friend

CEO
Karen Krumeich

CFO

Balance Sheet

Forecast net debt (US$m)

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	7.1	28.2	(77.5)
Relative	3.2	19.1	(78.4)
52 week high/low	US$6.0/US$0.5

Financials

Edison Investment Research is terminating coverage on Kazia Therapeutics (KZA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun	Revenue (US$m)	EBITDA (US$m)	PBT (US$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2021A	10.7	(3.1)	(3.1)	(25.09)	N/A	N/A
2022A	0.0	(14.9)	(14.9)	(110.57)	N/A	N/A
2023E	0.0	(19.0)	(19.0)	(111.41)	N/A	N/A
2024E	10.8	(17.2)	(17.2)	(82.84)	N/A	N/A

Research

edison tv

Healthcare

10.05.22

Paxalisib: Beyond glioblastoma and commercial opportunity

edison tv

Healthcare

09.05.22

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

Healthcare

edison tv

11.05.22

EVT801, Kazia’s second programme, and capital markets

ADR Update

Healthcare

28.03.22

Kazia Therapeutics — Several upcoming catalysts

edison tv

Healthcare

10.02.22

Kazia Therapeutics: Edison Open House Healthcare 2022

edison tv

Healthcare

25.10.21

Kazia Therapeutics – introducing novel asset EVT-801

ADR Update

Healthcare

14.10.21

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Update

Healthcare

13.10.21

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

edison tv

Healthcare

19.05.21

Kazia Therapeutics – overview and update with CEO James Garner

ADR Update

Healthcare

20.04.21

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Update

Healthcare

19.04.21

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

ADR Update

Healthcare

30.03.21

Kazia Therapeutics — Paxalisib Chinese rights licensed

Update

Healthcare

29.03.21

Kazia Therapeutics — Paxalisib Chinese rights licensed

ADR Update

Healthcare

08.03.21

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Update

Healthcare

01.03.21

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

edison tv

Healthcare

03.02.21

Kazia Therapeutics – Edison Open House interview

ADR Update

Healthcare

11.12.20

Kazia Therapeutics — Cantrixil final Phase I data reported

Update

Healthcare

10.12.20

Kazia Therapeutics — Cantrixil final Phase I data reported

ADR Update

Healthcare

02.12.20

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Update

Healthcare

24.11.20

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Initiation

Healthcare

28.08.20

Kazia Therapeutics — Bringing a vetted drug class to the brain

Update

Healthcare

31.03.20

Kazia Therapeutics — Paxalisib trial still on track for H220 start

ADR Update

Healthcare

13.01.20

Kazia Therapeutics — An agile pivot

Update

Healthcare

13.01.20

Kazia Therapeutics — An agile pivot

ADR Update

Healthcare

02.12.19

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

edison tv

Healthcare

25.11.19

Executive interview – Kazia Therapeutics

Update

Healthcare

25.11.19

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Update

Healthcare

05.09.19

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

ADR Outlook

Healthcare

21.06.19

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Outlook

Healthcare

21.06.19

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

ADR Update

Healthcare

01.04.19

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Update

Healthcare

29.03.19

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

ADR Update

Healthcare

29.10.18

Kazia Therapeutics — New indications for GDC-0084

Update

Healthcare

29.10.18

Kazia Therapeutics — New indications for GDC-0084

ADR Update

Healthcare

19.09.18

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Update

Healthcare

19.09.18

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Outlook

Healthcare

13.05.18

Kazia Therapeutics — GDC-0084 Phase II underway

ADR Outlook

Healthcare

11.05.18

Kazia Therapeutics — GDC-0084 Phase II underway

Update

Healthcare

11.09.17

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Update

Healthcare

11.09.17

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Outlook

Healthcare

25.05.17

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Outlook

Healthcare

22.05.17

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Update

Healthcare

31.10.16

Novogen — Update 31 October 2016

ADR Update

Healthcare

11.05.16

Novogen — Update 11 May 2016

Update

Healthcare

09.05.16

Novogen — Update 9 May 2016

thematic

Financials

09.05.23

IFRS 17: Impact on life assurance companies

thematic

TMT

25.04.23

MediaWatch – April 2023

thematic

Consumer

21.04.23

ConsumerWatch – April 2023

thematic

Industrials

13.04.23

Quantum computing: A booming industry

thematic

Metals & Mining

28.03.23

Critical minerals: The investment vacuum

thematic

Financials

17.03.23

Crypto, are you dead yet?

thematic

Industrials

27.02.23

UK housebuilders

thematic

Investment Companies

13.02.23

European equities

thematic

Investment Companies

08.02.23

Listed Private Equity

thematic

Metals & Mining

01.02.23

Lithium’s adolescence

Concept of energy storage unit consisting of multiple conected containers with batteries. 3d rednering.

thematic

Industrials

01.02.23

Battery energy storage

Digital Marketing and Internet Media Technology Platform

thematic

TMT

31.01.23

MediaWatch – January 2023

thematic

Investment Companies

27.01.23

Vietnamese equities: Due a comeback?

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Consumer

23.01.23

ConsumerWatch – January 2023

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

30.11.22

Investment companies: Latin America is worthy of consideration

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Real Estate

11.11.22

South African industrial property fundamentals are strong

thematic

Metals & Mining

08.11.22

Lepidico: Offer closes, oversubscribed

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

03.11.22

UK motor P&C insurers series

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Real Estate

24.10.22

South African retail property funds remain resilient

thematic

Consumer

13.10.22

ConsumerWatch – October 2022

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

Consumer

03.10.22

Food tech – At the forefront of food innovation

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Consumer

18.07.22

ConsumerWatch – July 2022

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Industrials

22.06.22

A new paradigm for space

thematic

30.05.22

Geopolitical conflict to drive renewables surge

thematic

Industrials

25.05.22

The emergence of mega-constellations

thematic

Industrials

23.05.22

Internet in the sky

thematic

12.05.22

Global markets: Valuation ‘normalisation’ continues

thematic

Financials

11.05.22

Revisiting IPOs in London

thematic

TMT

11.05.22

Direct tech investors

thematic

Investment Companies

10.05.22

The case for US capital markets

thematic

Industrials

10.05.22

Truth creates light

thematic

Industrials

09.05.22

All-seeing eye in the sky

thematic

Metals & Mining

27.04.22

Five (more) things every investor should know about lithium and Lepidico

thematic

Healthcare

26.04.22

24.03.22

Circular economy business models

thematic

Metals & Mining

21.03.22

04.02.22

Moving from a vegan January to a sustainable one

thematic

Industrials

02.02.22

BayWa – Focus on sustainability

thematic

19.01.22

Global perspectives: Earnings momentum still positive

thematic

Consumer

10.01.22

Cultivated meat – Engineering the growth of alternative meats

thematic

Metals & Mining

13.12.21

10.11.21

Artificial intelligence in drug discovery

thematic

Industrials

01.11.21

29.09.21

09.09.21

06.09.21

23.08.21

28.07.21

Finding the sea of green – The opportunity and options for shipping green H2

thematic

Healthcare

27.07.21

18.05.21

The circular economy

thematic

29.04.21

Equity strategy and market outlook – April 2021

thematic

Oil & Gas

28.04.21

Decarbonisation

thematic

Industrials

20.04.21

17.03.21

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

28.01.21

07.12.20

29.10.20

16.08.20

24.06.20

08.04.20

27.02.20

12.12.19

30.10.19

Edison Exhibits- antibiotic development

thematic

24.10.19

Past the peak of political risk?

thematic

Industrials

17.10.19

Water – The real liquidity crisis

thematic

17.10.19

Illuminator – October Update

thematic

Industrials

16.10.19

14.08.19

Illuminator: August Update

thematic

14.08.19

Staying focused on the facts – the risks remain in place

thematic

Investment Companies

07.08.19

Post Woodford- A spotlight on smaller company liquidity

thematic

TMT

05.08.19

European video games

thematic

25.07.19

Equity strategy and market outlook – July 2019

thematic

Healthcare

17.07.19

10.07.19

Diversification and scale for online success

thematic

Financials

03.07.19

26.06.19

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

06.06.19

Could the US Fed be enabling a continuation of the trade war?

thematic

Investment Companies

05.06.19

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

20.05.19

Shifting trade politics should not be ignored

thematic

Metals & Mining

16.05.19

Alliance Mineral Assets secures strategic investment from Galaxy and Jiangxi

thematic

Financials

14.05.19

Time value of money

thematic

TMT

08.05.19

24.04.19

Piedmont Lithium increases its mineral resource estimate by 21%

thematic

18.04.19

Equity strategy and market outlook – April 2019

thematic

Financials

15.04.19

Cash flow

thematic

09.04.19

Stronger survey data quashes recession fears for now

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

08.04.19

Industrial Automation

thematic

Oil & Gas

03.04.19

26.03.19

Types of investment trusts

thematic

21.03.19

Brexit: EU can do it if you really want…

thematic

Oil & Gas

20.03.19

Orinduik resource upgrade for Eco Atlantic offshore Guyana

thematic

14.03.19

Brexit: PM May’s deal may finally be in sight

thematic

Oil & Gas

13.03.19

No moveable hydrocarbons in Alaskan Winx-1 well

thematic

Oil & Gas

12.03.19

04.03.19

26.02.19

UK video games – Heterogeneous not homogeneous

thematic

14.02.19

Market outlook: balanced but still biased to upside

thematic

Financials

08.02.19

Enterprise versus equity valuation

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

28.01.19

ECB fiddles as eurozone turns

thematic

Metals & Mining

22.01.19

Gold stars and black holes

thematic

Financials

15.01.19

Deutsche Börse’s Scale

thematic

Financials

08.01.19

20.11.18

25.09.18

04.09.18

Tullow spuds Cormorant well offshore Namibia

thematic

Oil & Gas

20.08.18

Southern gas corridor to the EU nears agreement

thematic

13.08.18

Turkey:When risks collide

thematic

Oil & Gas

01.08.18

28.03.18

07.02.18

13.12.17

Kosmos exploration hiccups

thematic

Oil & Gas

06.12.17

Positive news from Genel’s Taq Taq

thematic

24.11.17

Economic surprise accelerating

thematic

Oil & Gas

20.11.17

Ludicrous growth of the EV

thematic

Oil & Gas

07.11.17

Tullow’s Araku result completes our 2017 wells to watch list

thematic

Oil & Gas

16.10.17

Fancy a Ferrari or an EV?

thematic

Oil & Gas

10.10.17

Verbier delivers after sidetrack

thematic

09.10.17

Economic data surprising to the upside in Q3

thematic

Oil & Gas

03.10.17

Revealing Big Oil hurdle rates

thematic

28.09.17

Earnings momentum – 2017 forecasts drifting slowly lower

thematic

Oil & Gas

26.09.17

Fatala well latest disappointment offshore West Africa

thematic

Oil & Gas

18.09.17

Partridge and Verbier fail to find oil

thematic

12.09.17

Interesting times for central bankers

thematic

Oil & Gas

17.08.17

08.08.17

Kosmos searching for more investors

thematic

Oil & Gas

26.07.17

21.06.17

ASCO 2017

thematic

21.06.17

Equity risks are rising: economic surprises turning lower

thematic

Oil & Gas

20.06.17

07.06.17

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – August 2023

Equity strategy and market outlook – July 2023

Equity strategy and market outlook – June 2023

Thematics

Latest

The long and winding road

MediaWatch – July 2023

ConsumerWatch – July 2023

About Edison

About Edison

Careers

Kazia Therapeutics (NASDAQ: KZIA)

Latest Insights

Kazia Therapeutics — Reinvestment period with increased R&D focus

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Kazia Therapeutics — Q123 cash flows in line with our estimates

Equity Analyst

Key Management

Balance Sheet

Share Price Performance

Financials

Research

Paxalisib: Beyond glioblastoma and commercial opportunity

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

EVT801, Kazia’s second programme, and capital markets

Kazia Therapeutics — Several upcoming catalysts

Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Kazia Therapeutics – overview and update with CEO James Garner

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Kazia Therapeutics — Paxalisib Chinese rights licensed

Kazia Therapeutics — Paxalisib Chinese rights licensed

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Kazia Therapeutics – Edison Open House interview

Kazia Therapeutics — Cantrixil final Phase I data reported

Kazia Therapeutics — Cantrixil final Phase I data reported

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Kazia Therapeutics — Bringing a vetted drug class to the brain

Kazia Therapeutics — Paxalisib trial still on track for H220 start

Kazia Therapeutics — An agile pivot

Kazia Therapeutics — An agile pivot

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Executive interview – Kazia Therapeutics

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Kazia Therapeutics — New indications for GDC-0084

Kazia Therapeutics — New indications for GDC-0084

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Kazia Therapeutics — GDC-0084 Phase II underway

Kazia Therapeutics — GDC-0084 Phase II underway

Novogen — GDC-0084 Phase II on track to commence Q417

Novogen — GDC-0084 Phase II on track to commence Q417

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Novogen — Update 31 October 2016

Novogen — Update 11 May 2016

Novogen — Update 9 May 2016

IFRS 17: Impact on life assurance companies

MediaWatch – April 2023

ConsumerWatch – April 2023

Quantum computing: A booming industry

Critical minerals: The investment vacuum

Crypto, are you dead yet?

UK housebuilders